ORMP
Price
$2.41
Change
+$0.01 (+0.42%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
98.41M
49 days until earnings call
SONN
Price
$5.17
Change
-$0.16 (-3.00%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
36.39M
Interact to see
Advertisement

ORMP vs SONN

Header iconORMP vs SONN Comparison
Open Charts ORMP vs SONNBanner chart's image
Oramed Pharmaceuticals
Price$2.41
Change+$0.01 (+0.42%)
VolumeN/A
Capitalization98.41M
Sonnet BioTherapeutics Holdings
Price$5.17
Change-$0.16 (-3.00%)
Volume$5.33K
Capitalization36.39M
ORMP vs SONN Comparison Chart in %
Loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ORMP vs. SONN commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a StrongBuy and SONN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (ORMP: $2.41 vs. SONN: $5.17)
Brand notoriety: ORMP and SONN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORMP: 26% vs. SONN: 33%
Market capitalization -- ORMP: $98.41M vs. SONN: $36.39M
ORMP [@Biotechnology] is valued at $98.41M. SONN’s [@Biotechnology] market capitalization is $36.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORMP’s FA Score shows that 0 FA rating(s) are green whileSONN’s FA Score has 0 green FA rating(s).

  • ORMP’s FA Score: 0 green, 5 red.
  • SONN’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than SONN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORMP’s TA Score shows that 5 TA indicator(s) are bullish while SONN’s TA Score has 6 bullish TA indicator(s).

  • ORMP’s TA Score: 5 bullish, 5 bearish.
  • SONN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SONN is a better buy in the short-term than ORMP.

Price Growth

ORMP (@Biotechnology) experienced а +2.99% price change this week, while SONN (@Biotechnology) price change was -16.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

ORMP is expected to report earnings on Nov 14, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($98.4M) has a higher market cap than SONN($36.4M). ORMP has higher P/E ratio than SONN: ORMP (20.91) vs SONN (0.29). SONN YTD gains are higher at: 254.110 vs. ORMP (-0.413). SONN has higher annual earnings (EBITDA): -13.97M vs. ORMP (-22.07M). ORMP has more cash in the bank: 97.9M vs. SONN (321K). SONN has less debt than ORMP: SONN (68.8K) vs ORMP (912K). ORMP has higher revenues than SONN: ORMP (2M) vs SONN (1M).
ORMPSONNORMP / SONN
Capitalization98.4M36.4M270%
EBITDA-22.07M-13.97M158%
Gain YTD-0.413254.110-0%
P/E Ratio20.910.297,254%
Revenue2M1M200%
Total Cash97.9M321K30,498%
Total Debt912K68.8K1,326%
FUNDAMENTALS RATINGS
ORMP vs SONN: Fundamental Ratings
ORMP
SONN
OUTLOOK RATING
1..100
7821
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
4934
P/E GROWTH RATING
1..100
4396
SEASONALITY SCORE
1..100
8575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (53) in the Pharmaceuticals Other industry is in the same range as SONN (82) in the null industry. This means that ORMP’s stock grew similarly to SONN’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as SONN (100) in the null industry. This means that ORMP’s stock grew similarly to SONN’s over the last 12 months.

ORMP's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as SONN (100) in the null industry. This means that ORMP’s stock grew similarly to SONN’s over the last 12 months.

SONN's Price Growth Rating (34) in the null industry is in the same range as ORMP (49) in the Pharmaceuticals Other industry. This means that SONN’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for SONN (96) in the null industry. This means that ORMP’s stock grew somewhat faster than SONN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORMPSONN
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CYTK50.402.57
+5.37%
Cytokinetics
SION28.941.44
+5.24%
Sionna Therapeutics Inc
EDRY12.460.19
+1.54%
EuroDry Ltd
LMNR15.110.13
+0.87%
Limoneira Co
MO65.700.51
+0.78%
Altria Group

ORMP and

Correlation & Price change

A.I.dvisor tells us that ORMP and BCAB have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ORMP and BCAB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+0.42%
BCAB - ORMP
29%
Poorly correlated
+5.92%
VALN - ORMP
29%
Poorly correlated
-2.51%
FULC - ORMP
28%
Poorly correlated
+4.12%
PRLD - ORMP
27%
Poorly correlated
+23.44%
SONN - ORMP
27%
Poorly correlated
-3.00%
More

SONN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SONN has been closely correlated with PTHS. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SONN jumps, then PTHS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
-3.00%
PTHS - SONN
70%
Closely correlated
-2.23%
INKT - SONN
36%
Loosely correlated
+2.65%
MBIO - SONN
29%
Poorly correlated
-1.25%
SNBIF - SONN
28%
Poorly correlated
N/A
PRME - SONN
27%
Poorly correlated
-2.11%
More